# Arovella Therapeutics

Source: https://onco.cc/companies/arovella-therapeutics/  
OnCo record `arovella-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Arovella Therapeutics makes ready-made cell therapies from donor immune cells called iNKT cells, engineered to find cancer cells. Its first product, ALA-101, is in an early trial in people with lymphoma or leukaemia that carry the marker CD19.

## Summary

Arovella Therapeutics Limited (ASX: ALA) is an Australian company with a physical base at the Jumar Bioincubator in Melbourne. It engineers invariant natural killer T (iNKT) cells from healthy donors to carry a chimeric antigen receptor, giving an allogeneic, off-the-shelf product; the company says iNKT cells can also recognise lipid-bound CD1d through their invariant T cell receptor and kill through the NKG2D pathway. ALA-101 is a CD19-directed CAR-iNKT therapy for CD19-positive B-cell lymphomas and leukaemias, and ALA-105 is a Claudin 18.2-directed CAR-iNKT programme aimed at solid tumours. Its first registered cancer trial, NCT07518329, a phase 1 dose-escalation and expansion study of a single infusion of ALA-101 after fludarabine and cyclophosphamide conditioning at Australian sites, was posted on ClinicalTrials.gov in April 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Melbourne
- Type: cell-therapy
- Website: https://www.arovella.com/
- Ticker: ASX: ALA

## Notes

- Founding year not stated on the company website.
- CAR-iNKT has no dedicated technology record in OnCo; it is filed under CAR-T and allogeneic cell therapy.
- No financing rows recorded: ASX announcements were not read.
- Company website read on 29 October 2026.

## Sources

- Official website: https://www.arovella.com/
- ALA-101 programme page: https://www.arovella.com/ala-101-car19-inkt
- ClinicalTrials.gov: phase 1 trial of ALA-101 in CD19-positive lymphoma and leukaemia (NCT07518329): https://clinicaltrials.gov/study/NCT07518329

## Connected records

- cancers: [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/), [Claudin 18.2](https://onco.cc/targets/cldn18-2/)

---
JSON: https://onco.cc/api/v1/entities/arovella-therapeutics.json